Noxopharm Yönetim

Yönetim kriter kontrolleri 4/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Gisela Mautner

İcra Kurulu Başkanı

AU$491.6k

Toplam tazminat

CEO maaş yüzdesi	83.4%
CEO görev süresi	2.5yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	3.6yrs
Yönetim Kurulu ortalama görev süresi	4.4yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Gisela Mautner'un ücretlendirmesi Noxopharm'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Dec 31 2023	n/a	n/a	-AU$12m
Sep 30 2023	n/a	n/a	-AU$14m
Jun 30 2023	AU$492k	AU$410k	-AU$15m
Mar 31 2023	n/a	n/a	-AU$15m
Dec 31 2022	n/a	n/a	-AU$15m
Sep 30 2022	n/a	n/a	-AU$17m
Jun 30 2022	AU$1m	AU$201k	-AU$19m

Tazminat ve Piyasa: Gisela 'nin toplam tazminatı ($USD 323.65K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 649.63K ).

Tazminat ve Kazançlar: Gisela 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Gisela Mautner

2.5yrs

Görev süresi

AU$491,562

Tazminat

Dr. Gisela Mautner is Non-Executive Director of Nyrada Inc. from August 1, 2022. She serves as Director at Noxopharm Limited. She served as Chief Medical Officer at Noxopharm Limited since October 2019 unt...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Gisela Mautner	CEO, Executive MD & Director	2.5yrs	AU$491.56k	Veri yok
Shawn Van Boheemen	Chief Financial Officer	5.3yrs	Veri yok	Veri yok
Jeanette Bell	Chief Operating Officer	4.6yrs	Veri yok	Veri yok
John Wilkinson	Chief Scientific Officer of Oncology	2.6yrs	Veri yok	Veri yok
Olivier Laczka	Chief Scientific Officer of Inflammation	2.6yrs	Veri yok	Veri yok
David Franks	Company Secretary	7.6yrs	AU$16.49k	Veri yok

3.6yrs

Ortalama Görev Süresi

Deneyimli Yönetim: NOXO.F 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Gisela Mautner	CEO, Executive MD & Director	no data	AU$491.56k	Veri yok
Frederick Bart	Non-Executive Chairman	4.3yrs	AU$45.00k	2.57% $ 375.7k
Peter Marks	Non-Executive Deputy Chairman	8.4yrs	AU$60.00k	0.31% $ 45.0k
Boris Patkin	Non-Executive Director	4.4yrs	AU$56.69k	0.22% $ 31.5k

4.4yrs

Ortalama Görev Süresi

70yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: NOXO.F 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.4 yıldır).

Noxopharm Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Noxopharm Limited, Annual General Meeting, Nov 19, 2024

Noxopharm Limited, Annual General Meeting, Nov 16, 2023

Noxopharm Limited Announces Resignation of Dr. Graham Kelly as Non-Executive Director, Effective 20 September 2022

Noxopharm Limited, Annual General Meeting, Nov 17, 2022

Recent updates

Noxopharm Limited, Annual General Meeting, Nov 19, 2024

Noxopharm Limited, Annual General Meeting, Nov 16, 2023

Noxopharm Limited Reviews Safety Data from the Third Cohort of Patients from the Dose Escalation Part of the DARRT-2 Trial

Noxopharm Limited Announces Award of Federal Innovation Connections Grant

Noxopharm Limited Announces CEP-2 Safety Milestone Shows Veyonda Progress

Noxopharm Limited Announces Resignation of Dr. Graham Kelly as Non-Executive Director, Effective 20 September 2022

Noxopharm Limited, Annual General Meeting, Nov 17, 2022

Noxopharm Limited Reviews the Safety Data from the First Cohort of Patients in the Trial

Noxopharm Limited Announces DARRT-2 Trial Safety Milestone and European Site Activated

Noxopharm Limited Announces Mayo Clinic and Washington University Join Its Sarcoma Trial

Veyonda Abstract Published at ASCO Annual Meeting 2022

FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment

Noxopharm Limited Announces Phase 1 CEP-2 Sarcoma Trial is Underway with a First Patient Enrolled and Dosed At City of Hope in Los Angeles, California

Noxopharm Limited Announces First Patient Dosed in CEP-2 Sarcoma Trial at the US City of Hope Cancer Center

Noxopharm Limited Announces Veyonda Achieves Important U.S. Patent Claims

Noxopharm Announces Preclinical Data Further Supports Anti-Inflammatory Role of Idronoxil in the Treatment of COVID-19

Noxopharm Phase I Clinical Trial Shows Anti-Inflammatory Response in COVID-19 Patients

Noxopharm Limited Releases Preliminary Top Line Data of Its NOXCOVID Phase 1 Clinical Trial

Noxopharm Limited's DARRT-2 Study Receives IND Approval from FDA

Noxopharm Limited Updates the Market on Progress with its DARRT-2 Trial

Noxopharm Limited Announces the Release of Clinical Data Relating to the Experimental Radioligand

Noxopharm Limited Announces New Independent Trial Data Supports Potential of Veyonda as Major New Anti-Cancer Drug

Noxopharm Limited’s Veyonda to Begin First-Line Sarcoma Treatment Testing

Oxopharm Limited Announces That Its Cep-2 Study Will Open Shortly

Clinical Data Shows Noxopharm’s Veyonda May Prevent Cytokine Storm

Noxopharm IONIC Immuno-Oncology Trial Commences

Noxopharm Limited Announces Veyonda Approved to Move into Second and Final Stage of the NOXCOVID-1 Clinical Trial on the Advice of the Clinicians Treating the NOXCOVID-1 Patients

Noxopharm Limited Provides More Detailed Summary of Data from the Lupin Study That Formally Presented to the American Society of Clinical Oncology Genitourinary Cancers Symposium

Noxopharm Limited Reports the Publication in Abstract Form of the Latest Survival Data from the LuPIN Study

Noxopharm Limited Announces the Latest Formal Review by the NOXCOVID-1 Safety Steering Committee Cleared it to Advance to the Fifth and Final Dosage Cohort

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş